Although the blood glucose lowering effect of MD001 was lower than that of rosiglitazone, the MD001-mediated increase in fatty acid oxidation via PPARα activation suggests that MD001 may have favourable effects on hyperlipidaemia and obesity without inducing body weight gain, at least in part. This evidence concerns the gene PPARA and Obesity.